Michael, A.Popov, of Prime States Quantum Lab, London - Oxford, UK examines how gaps in our understanding of time, could unlock revolutions in cancer studies and epigenetics
Many joint discovery projects fail for a variety of reasons, including poor communication and data/reporting inconsistencies. Read this Whitepaper to discover how to optimize collaborative networked research in pharma.
From a better understanding of cancer genomes, clinicians can select the most suitable treatments available for a cancer patient.
Frustrated by the fight for prime lab space in the US, life sciences companies are exploring the surrounding suburbs of major clusters for more affordable research facilities.
Pharma treads a fine line to the tipping point where there is insufficient time to recoup a drug’s costs, due to the number of years left that the patent can run.